The notebook sat on a shelf in the lab manager's office for thirty years. Dark green cover, wire-bound, the pages softened by humidity and time. Inside were the formulations that built the company: viscosities, surfactant ratios, cure times, the exact sequence of additions that kept a batch from gelling prematurely. No one else knew them quite as well as the man who wrote them. When he retired, the notebook came down from the shelf. Three years later, a prospective buyer opened it during due diligence and quietly revised their offer downward.
That story repeats, in some form, in specialty chemical businesses across the country. The science is real. The institutional knowledge is deep. But the way it's held, in notebooks, in heads, in the tacit understanding of people who have been there long enough, is structurally fragile. And in a sale process, structural fragility costs money.
The 20-Year Problem
The scientific community has been studying knowledge loss for decades, and the numbers are not encouraging. The American Chemical Society's Chemical Abstracts Service has found that roughly 80% of scientific data becomes unavailable within 20 years of its creation. It doesn't disappear in a dramatic way. It just drifts: the original researcher moves on, the file format becomes obsolete, the notebook goes into a box, the box goes into storage.
For a specialty chemical company, that drift has a dollar amount attached to it. IP attorneys and M&A advisors have documented the valuation premium that comes from having formulation data that is documented, digitized, and version-controlled. Companies with well-managed IP portfolios are valued at roughly twice the multiple of those without. That gap doesn't come from having better chemistry. It comes from being able to prove what you know.
Trade Secrets Are Not What They Seem
The instinct many owners have is to keep formulations secret rather than document them. The logic makes sense on the surface: if it's not written down, no one can steal it. But trade secret protection in specialty chemicals is weaker than most people assume.
The core problem is that reverse engineering is legal. A competitor can purchase a finished product, take it to a contract lab, and work backward from the results. As long as they didn't breach a confidentiality agreement or improperly obtain your materials, they have done nothing wrong. Trade secret law protects against improper acquisition. It does not protect against a skilled formulator and a gas chromatograph.
The exposure on the other end is even more stark. A single disclosure event, a departing employee who mentions the wrong thing, a vendor who shares more than they should, can reduce the legal value of a trade secret to zero. Courts have held that once a secret is out, the protection is gone. There is no recovery.
That is not an argument for abandoning trade secret protection. It is an argument for not treating it as your only protection.
What Due Diligence Finds
When a private equity buyer runs IP due diligence on a specialty chemical company, they are looking for a clean ownership chain. They want to see that the formulation was developed by employees working within the scope of their employment, that assignment agreements are in place, and that the IP has not been contaminated by outside contributions that could create claims.
When that chain is missing or unclear, buyers have a legitimate basis to reduce their offer. The American Bar Association's M&A due diligence guidelines are specific on this point: gaps in IP ownership documentation are a recognized price-reduction lever. A buyer who finds inconsistencies is not being aggressive. They are being prudent.
The companies that navigate this cleanly are the ones that treated their formulation library as a managed asset rather than a historical record. Formulation management software, version control, authorship tracking, the kind of rigor that software companies have applied to their code for decades, is now accessible to chemical manufacturers at reasonable cost. The tools exist. The question is whether the investment gets made before a sale process begins or during one, when the leverage is gone.
The Chemist in the Room
None of this is a criticism of the scientists who built these businesses. The knowledge they carry is extraordinary. A senior formulation chemist who knows why a particular cure schedule works, who has seen ten thousand batches and can diagnose a problem from smell alone, is an asset that cannot be fully captured in any database. That knowledge should be honored.
But that knowledge should also be transferred. Not because the person might leave, though they might. Because the business is worth more when what they know can be understood, verified, and built upon by others. Documentation does not replace expertise. It frees expertise for harder problems.
AI tools are beginning to make this transfer more systematic. The same techniques that extract structured data from unstructured text can help translate years of lab notebooks into searchable, version-controlled records. They do not do the science. They handle the transcription and organization that makes the science legible to someone who wasn't there. It's worth noting that AI-assisted formulation optimization remains a 2028–2030 opportunity for most middle-market companies—the prerequisite is exactly this kind of prior data digitization work.
Specialty Chemicals in Transition
The broader M&A environment in specialty chemicals is active. Owners who are thinking about a sale in the next three to five years are in a market where buyers have options and where the premium for a clean, well-documented business is real. The dynamics are worth understanding before a process begins.
Our analysis of specialty chemicals M&A in 2026 covers the transaction environment in more detail, including where buyers are focusing and what the valuation spread looks like between businesses that are prepared and those that are not. For a detailed look at where AI is delivering measurable ROI in chemical manufacturing today, and where it isn't yet ready, see AI in Specialty Chemicals: What Actually Works.
The Asset That Decays
Every year that passes with formulations living in notebooks and chemists' heads, the competitive advantage they represent gets a little more fragile. The person who knows the most gets a year older. The notebook gets a year more weathered. The gap between what the business knows and what can be proven, transferred, and defended in a sale grows wider.
Documented, digitized IP is not a luxury. It is the form that knowledge takes when it is ready to be valued.
A single disclosure event can reduce the legal value of a trade secret to zero. Courts have held that once a secret is out, the protection is gone.
Sources
- CAS (Chemical Abstracts Service) — 80% of scientific data becomes unavailable after 20 years
- PatentPC / Lexology — IP documentation and valuation premiums
- Life Science Leader — Reverse engineering and trade secret limitations in formulations
- American Bar Association — IP due diligence gaps as price-reduction lever
Buy. Build. Compound.